Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis

Advances in Therapy

Volumn 35, Issue 10, 2018, Pages 1626-1638

  Naya, Ian P ^a   Tombs, Lee ^b   Lipson, David A ^c   Compton, Chris ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Precise Approach Ltd   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Add on LAMA; Clinically important deteriorations; COPD; Fluticasone furoate vilanterol; Fluticasone propionate salmeterol; Respiratory; Triple therapy; Umeclidinium

Indexed keywords

FLUTICASONE FUROATE PLUS VILANTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; UMECLIDINIUM; BENZYL ALCOHOL DERIVATIVE; CHLOROBENZENE; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINUCLIDINE DERIVATIVE; RESPIRATORY TRACT AGENT; VILANTEROL;

ADULT; ARTICLE; BACKACHE; BRONCHODILATATION; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICALLY IMPORTANT DETERIORATION; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPEN STUDY; PNEUMONIA; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK REDUCTION; ST. GEORGE RESPIRATORY QUESTIONNAIRE; AGED; DRUG EFFECT; PATHOPHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

AGED; BENZYL ALCOHOLS; CHLOROBENZENES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FLUTICASONE-SALMETEROL DRUG COMBINATION; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY SYSTEM AGENTS; SECONDARY PREVENTION; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

EID: 85053451066     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-018-0771-4     Document Type: Article

References (44)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated 2018. http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf. Accessed Jan 23, 2018
2. World Health Organization (WHO). Chronic obstructive pulmonary disease (COPD) fact sheet. Updated November 2017. http://www.who.int/mediacentre/factsheets/fs315/en/. Accessed Nov 16, 2017
3. Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14–23
4. Jenkins CR, Celli B, Anderson JA, et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J. 2012;39(1):38–45
5. Jenkins CR, Postma DS, Anzueto AR, et al. Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease. BMC Pulm Med. 2015;15:97
6. Punekar YS, Naya I, Small M, et al. Bronchodilator reliever use and its association with the economic and humanistic burden of COPD: a propensity-matched study. J Med Econ. 2017;20(1):28–36
7. Punekar YS, Mullerova H, Small M, et al. Prevalence and burden of dyspnoea among patients with chronic obstructive pulmonary disease in five European countries. Pulm Ther. 2016;2(1):59–72
8. Punekar YS, Sharma S, Pahwa A, Takyar J, Naya I, Jones PW. Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis. Respir Res. 2017;18(1):86
9. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest. 2004;125(1):249–59
10. Cazzola M, Page C. Long-acting bronchodilators in COPD: where are we now and where are we going? Breathe. 2014;10(2):111–20
11. Short PM, Williamson PA, Elder DHJ, Lipworth SIW, Schembri S, Lipworth BJ. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting beta-agonist therapy in COPD. Chest. 2012;141(1):81–6
12. Simeone JC, Luthra R, Kaila S, et al. Initiation of triple therapy maintenance treatment among patients with COPD in the US. Int J Chron Obstruct Pulmon Dis. 2017;12:73–83
13. Kozma CM, Paris AL, Plauschinat CA, Slaton T, Mackowiak JI. Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study. BMC Pulm Med. 2011;11:61
14. Lee TA, Wilke C, Joo M, et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2009;169(15):1403–10
15. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–54
16. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–89
17. Frith PA, Thompson PJ, Ratnavadivel R, et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Thorax. 2015;70(6):519–27
18. 2 agonists for patients with COPD: pooled results of randomized placebo-controlled trials. Pulm Ther. 2016;2:43–58
19. Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–46
20. Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–73
21. Anzueto AR, Vogelmeier CF, Kostikas K, et al. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1325–37
22. Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11:1413–24
23. Singh D, D’Urzo AD, Chuecos F, Munoz A, Garcia Gil E. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. Respir Res. 2017;18(1):106
24. Siler TM, Kerwin E, Singletary K, Brooks J, Church A. Efficacy and safety of umeclidinium added to fluticasone propionate/salmeterol in patients with COPD: results of two randomized, double-blind studies. Chron Obstruct Pulmon Dis. 2016;13(1):1–10
25. Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomized studies. Respir Med. 2015;109(9):1155–63
26. GSK. Incruse summary of product characteristics. Updated 2017. https://www.medicines.org.uk/emc/medicine/29394. Accessed Feb 2, 2018
27. GSK. Highlights of prescribing information. Updated 2017. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Incruse_Ellipta/pdf/INCRUSE-ELLIPTA-PI-PIL.PDF. Accessed Feb 2, 2018
28. Celli BR, MacNee W, Force AET. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–46
29. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated 2016. http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/. Accessed Nov 17, 2017
30. Vestbo J. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J. 2004;24(2):206–10
31. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J. 2008;31(4):869–73
32. Naya I, Tombs L, Mullerova H, Compton C, Jones P. Long-term outcome following first clinically important deterioration in COPD. Eur Respir J. 2016;48(Suppl 60):PA304
33. Rabe KF, Halpin D, Martinez F, et al. Predicting long-term outcomes and future deterioration in COPD with a composite endpoint: post hoc analysis of the UPLIFT study. Am J Respir Crit Care Med. 2017;195:A2717
34. Singh D, Papi A, Vezzoli S, et al. CHF5993 pMDI (extrafine Beclometasone Dipropionate:BDP, Formoterol Fumarate:FF, Glycopyrronium Bromide:GB) reduces clinically important deteriorations (CID) in COPD: post hoc analysis of TRILOGY study. Eur Respir J. 2017;50(Suppl 61):PA533
35. Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–80
36. Anzueto AR, Kostikas K, Shen S, et al. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration versus salmeterol/fluticasone: the FLAME study. Eur Respir J. 2017;50(Suppl 61):PA3255
37. Singh D, Papi A, Vezzoli S, et al. Effect of CHF5993 pMDI (extrafine Beclometasone Dipropionate:BDP, Formoterol Fumarate:FF, Glycopyrronium Bromide:GB) on clinically important deteriorations (CID) in COPD: post hoc analysis of TRINITY study. Eur Respir J. 2017;50(Suppl 61):PA3949
38. Buhl R, McGarvey L, Korn S, et al. Benefits of tiotropium + olodaterol over tiotropium at delaying clinically significant events in patients with COPD classified as GOLD B. Am J Respir Crit Care Med. 2016;193:A6779
39. Naya I, Barnacle H, Birk R, et al. Clinically important deterioration in advanced COPD patients using single inhaler triple therapy: results from the FULFIL study. Eur Respir J. 2017;50(Suppl 61):PA3248
40. Wang MT, Liou JT, Lin CW, et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med. 2018;178(2):229–38
41. Feldman G, Maltais F, Khindri S, et al. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 mug compared with tiotropium 18 mug in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:719–30
42. Manickam R, Asija A, Aronow WS. Umeclidinium for treating COPD: an evaluation of pharmacologic properties, safety and clinical use. Expert Opin Drug Saf. 2014;13(11):1555–61
43. Sion KYJ, Huisman EL, Punekar YS, Naya I, Ismaila A. A network meta-analysis of long-acting muscarinic antagonist (LAMA) and long-acting b2-agonist (LABA) combinations in COPD. Pulm Ther. 2017;3(2):297–316
44. Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–84